

Dementia - PET (HD-8.2)

HD.DM.0008.2.A

Amyloid PET Brain (CPT® 78814 or 78811)

Amyloid Brain PET is medically necessary when a diagnosis of MCI or dementia due to Alzheimer's disease is suspected based on cognitive testing, and evaluation including structural brain imaging has been completed, in ANY of the following clinical scenarios:

- Individuals with MCI or dementia who are <65 years of age and in whom AD is suspected
- Individuals with MCI or dementia that could be consistent with amnesic AD pathology with onset at ≥65 years of age
- Individuals with MCI or dementia that could be consistent with AD but has atypical clinical features
- Individuals with MCI or dementia with equivocal or inconclusive results on CSF biomarkers
- To inform the prognosis of individuals with MCI due to suspected AD pathology
- To determine eligibility for treatment with amyloid targeting therapy and to monitor response (as listed in the criteria in **Imaging Related to Alzheimer's Treatment with Amyloid Reduction Medications (HD-8.5)**).

References

HD.DM.0008.2.A

1. Soderlund KA, Austin MJ, Ben-Haim S, et al. ACR Appropriateness Criteria® Dementia. Available at <https://acsearch.acr.org/docs/3111292/Narrative/>. American College of Radiology. 2024.
2. Rabinovici GD, Knopman DS, Arbizu J, et al. Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. *J Nucl Med*. Published online January 8, 2025. doi:10.2967/jnumed.124.268756
3. Jack CR Jr, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. *Alzheimers Dement*. 2024;20(8):5143-5169. doi:10.1002/alz.13859